Physician profile
Michael H Shannon
NPI 1366551285
$698,091.65
in general payments reported to CMS, 2019-2025
12 companies · $117K in 2025
The $117K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214K · 2020: $39K · 2021: $94K · 2022: $104K · 2023: $80K · 2024: $50K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $166K · Consulting Fee: $45K · Travel and Lodging: $28K · Food and Beverage: $7,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $165,796.94 |
| Consulting Fee | $45,346.79 |
| Travel and Lodging | $27,869.54 |
| Food and Beverage | $7,133.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $415,574.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $159,173.49 | 2021-2025 | |
| Lilly USA, LLC | $74,345.66 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44,702.76 | 2019 | |
| Eli Lilly and Company | $2,027.19 | 2019-2024 | Kisunla, Zepbound |
| Shire North American Group INC | $1,240.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $254.62 | 2019-2022 | |
| Amgen INC. | $233.45 | 2019 | |
| Genentech USA, INC. | $150.00 | 2021 | |
| Corcept Therapeutics | $139.82 | 2025 | Korlym |
| Vifor Pharma, INC. | $124.98 | 2021 | |
| Abbvie INC. | $124.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.